, Tracking Stock Market Picks
Enter Symbol:
Stemcells, Inc. (STEM) [hlAlert]

down 83.88 %

Stemcells, Inc. (STEM) rated Buy with price target $2.60 by Ascendiant Capital Markets

Posted on: Wednesday,  Oct 17, 2012  8:25 AM ET by Ascendiant Capital Markets

Ascendiant Capital Markets rated Buy Stemcells, Inc. (NASDAQ: STEM) on 10/17/2012, when the stock price was $2.42. Since
then, Stemcells, Inc. has lost 83.88% as of 11/24/2015's recent price of $0.39.
If you would have followed this Ascendiant Capital Markets's recommendation on STEM, you would have lost 83.88% of your investment in 1133 days.

StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

Ascendiant Capital Markets is led by George Santana, who has nearly twenty years of equity research experience in the United States and foreign markets. During his career, Mr. Santana has been recognized six consecutive times in the Institutional Investor magazine poll of top analysts.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/17/2012 8:25 AM Buy
2.42 2.60
as of 12/31/2012
1 Week up  3.16 %
1 Month down  -9.44 %
3 Months down  -32.64 %
1 YTD down  -32.64 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy